

Element 25 Limited (E25)

Manganese Meets the Mighty Mississippi

E25 has released a Feasibility Study (FS) on its proposed Battery Manganese Plant in Louisiana. The plant will upgrade ore from its operating Butcherbird mine in WA to manganese for use in the US EV auto supply chain. The FS delivered a higher NPV than the scoping study, due to higher production rates and increased revenue from the sale of co-products. The impact on a per share basis was somewhat offset by higher capital costs and an increase in equity funding. Our price target increases modestly to A\$3.06/sh (prev. A\$3.04/sh). This represents 285% upside and we expect the gap to close as more offtake is announced this month and project FID approaches mid '23.

Higher production and pricing offsets higher costs

- High grade HPMSM represents 100% of production, up from 75% in the Jan-22 Scoping Study
- The Scoping Study envisaged 25% of production as low priced fertiliser manganese (50% price achievement) flowsheet optimisation has allowed for 100% HPMSM
- While we had forecast capital and operating costs 30% higher than the scoping study due to sector inflation, capital and operating costs came in 102% and 113% ahead of the scoping study respectively (Figure 1)
- Combining these changes lifts our NPV, our battery manganese NPV increases 78% to A\$654m (Figure 2)

Funding and offtake

- We expect binding offtake to be announced this month, which will likely include debt funding for the project
- We forecast 60% debt gearing on capex for A\$243m, with a further A\$100m in equity in addition to the existing cash balance and interim operating cashflow
- Despite an increase to the project NPV, on a per share basis this is offset given the additional equity required to fund the higher capex (prev. equity raising of A\$35m)

Manganese is an essential battery material

- Manganese is the cheapest of the NMC cathode materials (nickel, manganese and cobalt). NMC make up the majority of battery designs (Figure 3)
- E25's maiden 130ktpa line could satisfy 4% of 2030 global battery quality manganese demand (Figure 4)
- E25 is getting strong interest in offtake given over 95% of current battery manganese is sourced from China and E25's processing is less carbon intensive (Figure 5)

Key Dates Ahead

- April.23 Battery manganese offtake expected
- Jun.Q'26 First production of battery grade Mn

Buy Share Price: A\$0.80


Target Price: A\$3.06

Company Data	
Shares – ordinary (M)	184
Market capitalisation (\$M)	146
12 month low/high (\$)	0.43/ 1.44
Average monthly turnover (\$M)	4.9
GICS Industry	Metals & Mining

Financial Summary (fully diluted/normalised)

Year End June	2022A	2023F	2024F	2025F	2026F
Revenue (\$m)	27.3	38.9	148.4	214.7	220.4
Costs (\$m)	42.9	44.8	104.6	146.2	155.3
EBITDA (\$m)	-15.6	-5.8	43.8	68.6	65.1
NPAT (\$m)	-17.6	-5.9	36.4	39.3	34.2
EPS (cps)	-11.7	-3.5	12.6	12.7	11.1
EPS growth (%)	62.8	-237.9	127.5	0.5	-12.8
PER (x)	-6.8	-22.9	6.3	6.3	7.2
Free Cashflow (\$M)	-19.5	-4.8	40.4	47.8	38.8
FCFPS (¢ps)	-10.6	-2.6	21.9	26.0	21.1
PFCFPS (x)	-7.5	-30.2	3.6	3.1	3.8
Enterprise Value (\$M)	131	122	131	247	334
EV / EBITDA (x)	-8.4	-20.8	3.0	3.6	5.1
Payout ratio (%)	0.0	0.0	0.0	0.0	0.0
Dividend (cps)	0.0	0.0	0.0	0.0	0.0
Yield (%)	0.0	0.0	0.0	0.0	0.0
Franking (%)	0.0	0.0	0.0	0.0	0.0

E25 - performance over one year



Disclosure and Disclaimer

This report must be read with the disclosure and disclaimer on the final page of this document. The analyst preparing this report has a beneficial interest in 78,044 shares in this company. Petra Capital was lead manager and bookrunner for this company's placement to raise \$35m at A\$1.12/sh on 15 November 2022, for which fees were received.



Analysis

Element 25 Limite	ed (E2	25)					
Year end 30 June							1
							1
Recommendation						Buy	1
Price	\$					0.80	1
Target Price (12-month)	\$					3.06	1
Upside / (Downside)	%					285%	
50	•						
52 week high / low	\$				1.4	4 - 0.43	
Market capitalisation	\$m					146 184	
Shares on issue Options + Future Equity	no. no.					157	
Shares on issue (diluted)	no.					341	
Griares on issue (diluted)	110.					541	
PROFIT & LOSS		2022A	2023E	2024E	2025E	2026E	A
Revenue	\$M	27	39	148	215	220	A
Operating Costs	\$M	(38)	(40)	(100)	(142)	(151)	Μ
Exploration	\$М	(1)	(1)	(1)	(1)	(1)	R
Other	\$M	(4)	(4)	(4)	(4)	(4)	R
EBITDA	\$M	(16)	(6)	44	69	65	н
Dep. & Amort.	\$M	(2)	(1)	(2)	(3)	(4)	
EBIT	\$M	(17)	(6)	42	66	61	в
Net Interest	\$M	(0)	1	(4)	(10)	(12)	
Pre-Tax Profit	\$M	(18)	(6)	38	56	49	R
Tax	\$M	-	-	(2)	(17)	(15)	R
Net Profit	\$M	(18)	(6)	36	39	34	Р
Abnormal	\$M	-	-	-	-	-	
Reported Profit	\$M	(18)	(6)	36	39	34	Ρ
							Т
CASH FLOW		2022A	2023E	2024E	2025E	2026E	G
Revenue	\$M	21	39	148	215	220	R
Costs	\$M	(41)	(44)	(104)	(146)	(155)	
Tax Payable	\$M	-	-	-	(11)	(14)	M
Other	\$M	1	1	(4)	(21)	(27)	M
Operating Cashflow	\$M	(19)	(5)	40	48	39	0
Capex	\$M	(2)	(20)	(149)	(164)	(125)	
Exploration	\$M	-	(1)	(1)	(1)	(1)	Н
Acquisitions Other	\$M		-		-	-	0
	\$M				-	-	R
Investing Cashflow	\$M \$M	(2) 1	(20) 35	(149) 100	(164)	(126)	70
Equity Issues Debt Raised / (repaid)	\$Μ	1	30	243	-	-	
Free Cashflow	\$M	(21)	(25)	(109)	(116)	(87)	60
Surplus Cash Flow	\$M	(20)	10	234	(116)	(87)	50
		(-)	-	-	(-)	(-)	
BALANCE SHEET		2022A	2023E	2024E	2025E	2026E	40
Cash	\$M	15	25	258	142	55	30
Other Current	\$M	16	16	16	27	42	
Total Current	\$M	31	41	274	169	96	20
PP&E & Exploration	\$M	22	41	188	349	471	10
Other	\$M	2	2	2	2	2	TC.
Total NC Assets	\$M	24	43	190	351	473	
Total Assets	\$M	55	84	465	521	570	
Current Liab	\$M	8	8	8	8	8	
Non Current Liab	\$M	1	1	243	243	243	
Total Liabilities	\$M	9	9	252	252	252	С
Net Assets	\$M	46	75	213	269	318	
Equity	\$M	46	75	213	269	318	
Total Debt	\$M	-	-	243	243	243	
Net Debt	\$M	(15)	(25)	(16)	101	188	
RATIO ANALYSIS		2022A	2023E	2024E	2025E	2026E	
EPS	¢	(11.7)	(3.5)	12.6	12.7	11.1	
PER	x	(6.8)	(22.9)	6.3x	6.3x	7.2x	
EPS Growth	%	63%	(238%)	127%	1%	(13%)	
EV/EBITDA	x	(8.4)	(20.8)	3.0x	3.6x	(10,0) 5.1x	(
EV/OCF	x	(6.7)	(25.1)	3.2x	(11.6)	(12.5)	(1
FCFPS	¢	(11.4)	(13.7)	(59.3)	(63.3)	(47.4)	
FCF Yield	%	(14%)	(17%)	(75%)	(80%)	(60%)	(1
DPS	¢	1			1.1	-	(2
Yield	%	-	-	-	-	-	
Franking	%	-	-	-	0%	0%	
Payout Ratio	%						

-

(221) **(57%)**

(64%)

(81%)

(38%)

% %

x % % % %


-

n.m. (15%)

(17%)

(16%)

(8%)



----- ASX 200


ASSUMPTIONS		2022A	2023E	2024E	2025E	2026E
A\$/US\$ exchange rate	\$	0.73	0.68	0.70	0.73	0.75
Mn Conc ref price (44%)	US\$/dmtu	5.83	5.68	5.98	6.20	6.20
Realised Mn price	US\$/dmtu	3.24	3.83	4.44	4.67	4.66
Realised Mn conc price	US\$/t	94	124	148	155	154
High Purity Mn price	US\$/t	1,725	2,250	2,550	2,550	2,550

BUTCHERBIRD MINE LIFE									
	Contained Mn	Grade (%)	Years						
Reserves	4.3	10%	13						
Resources	21.6	10%	65						
Petra Mining Inventory	8.9	10%	20						

PRODUCTION & COSTS		2022A	2023E	2024E	2025E	2026E
Tonnes processed	Mtpa	0.9	1.1	2.7	3.9	3.9
Grade	g/t	10.8%	10.3%	10.3%	10.3%	10.3%
Recovery	%	77%	78%	83%	83%	83%
Mn Conc Production	kt	224	240	700	1,007	1,007
Mn Conc Sales	kt	162	212	700	1,007	1,003
Operating Costs	US\$/t	104	114	100	102	105
HP Mn Sales	kt	-	-	-	-	4
Operating Costs	US\$/t					1,800



CASH GENERATION



-				
76%	VALUATION (10% discount rate)	A\$m	A\$/Sh	%
5	Butcherbird Manganese Conc	386	1.13	
30%	High Purity Manganese	654	1.92	
28%	Exploration	10	0.03	
13%	Net Cash	25	0.07	
11%	Corporate	(33)	(0.10)	P/NPV
30%	Group NPV	1,042	3.06	0.26

Source: Petra Capital

Payout Ratio

Gearing D/E

EBIT Margin

Interest Cover EBITDA Margin

Return On Assets

Return On Equity

Eff Tax rate (cash tax)

90%

19%

15%

30%

7 **32%** 31%

114%

11 **29%** 28%

22%

17%



Study Results - Higher production and prices offset cost inflation

E25 has released a feasibility study for its High Purity Battery Manganese Plant in Louisiana. Compared to prior studies, key differences include:

- E25 has improved its flowsheet such that 100% of production is now battery grade product. The scoping study envisaged lower grade product (FGMSM)
- In addition, the company will produce a sulphate fertiliser as a by-product. Compared to the scoping study this has increased both costs and revenue (fertiliser revenues not broken out)
- Capital and operating costs have increased materially. The Scoping Study was premised on a Malaysian location, which has lower operating and capital costs than Louisiana. In addition, broader sector inflation has had an impact in the 14 months since the prior study was released
- The Louisiana location also allows E25 to access the tax credits from the Inflation Reduction Act, which positively impact the NPV. In addition, the location is preferred by tier one customers which improves the funding outlook for the project
- The net result is a 45% increase in the study NPV

Figure 1: E25 High Purity Battery Manganese Study Output

	Scoping Study (Jan-22)	Feasibility Study (Apr-23)	Variance
Ore Purchased (ktpa)	157	140	-11%
HPMSM Produced (ktpa)*	100	130	30%
FGMSM Produced (ktpa)	33	-	n.m.
HPMSM Price (Received)	1,950	2,557**	31%
FGMSM Price (Received)	900	n.m.	n.m.
Undiscounted Cashflow (US\$M)	141	155	10%
Project Life (Years)	20	28	40%
NPV ₈ Real (pre-tax)	890	1,662	87%
NPV ₈ Real (post-tax)	801	1,161	45%
IRR (Pre-tax) (%)	45	29	-36%
Operating Cost (US\$/t)	558	1,188	113%
Capital Cost (US\$m)	236	476	102%

Source: Company Reports, HPMSM = High Purity Manganese Sulphate, **Back calculated revenue, includes co-product revenues

Changes to our earnings and valuation

We make material changes to our earnings and NPV, including:


- Materially higher capital and operating costs for the HPMSM business (we had assumed capital and operating costs would be 30% above the scoping study)
- Higher HPMSM production rates in line with the base case study results we had previously assumed a first train of 65ktpa only as per the base case in the scoping study. The base case for the Feasibility Study is 130ktpa, with a second 65ktpa train entering production in Year 5
- Higher assumed revenue per tonne of US\$2,550/t in line with E25's study (prev. US\$1,950/t)
- First HPMSM production delayed by three quarters to June Q 2026
- Overall, our HPMSM plant NPV increases 78% from A\$365m to A\$654m
- We assume A\$100m in equity is required at FID (prev. A\$35m) due to the higher capital costs, assuming the project can be 60% debt financed
- While our NPV increases, due to the dilutive nature of additional capex, our NPV/sh increases modestly to A\$3.06/sh from A\$3.04/sh
- Our valuation remains lower than the study due to a higher discount rate (10% real) and additional conservatism on ramp up and costs despite this we still have 285% upside to our price target from the current share price




Figure 2: Changes to earnings and price target

			FY23			FY24			FY25	
		New	Old	% var	New	Old	% var	New	Old	% var
Revenue	A\$m	39	39	-	148	148	-	215	215	-
EBITDA	A\$m	(6)	(6)	-	44	48	(8%)	69	74	(7%)
EBIT	A\$m	(6)	(6)	-	42	46	(8%)	66	71	(7%)
NPAT	A\$m	(6)	(6)	-	36	40	(9%)	39	45	(12%)
EPS	Ac/sh	(3.5)	(3.4)	1%	12.6	18.3	(31%)	12.7	20.4	(38%)
DPS	Ac/sh	0.0	0.0	-	0.0	0.0	-	0.0	0.0	-
NPV	A\$m	1,042	761	37%						
NPV/sh	A\$/sh	3.06	3.04	1%						

Source: Petra Capital







Source: Future material demand for automotive lithium-based batteries - Chengjian Xu, Qiang Dai, Linda Gaines, Mingming Hu, Arnold Tukker & Bernhard Steubing








Source: Company Reports





Source: Company Reports



Petra Capital

Level 17, 14 Martin Place, Sydney NSW 2000 Level 5, 1 Collins Street, Melbourne VIC 3000

Director:	George Marias	+61 (0)2 9239 9601	gmarias@petracapital.com.au
Research (Resources):	Brett McKay	+61 (0)2 9239 9605	bmckay@petracapital.com.au
Research (Resources):	Hugh Stackpool	+61 (0)2 9239 9625	hstackpool@petracapital.com.au
Research (Resources):	David Brennan	+61 (0)2 9239 9630	dbrennan@petracapital.com.au
Research (Resources):	Andrew Harrington	+61 (0)2 9239 9614	aharrington@petracapital.com.au
Research (Resources):	Kieran Barratt	+61 (0)2 9239 9610	kbarratt@petracapital.com.au
Research (Resources):	Colin McLelland	+61 (0)2 9239 9639	cmclelland@petracapital.com.au
Research (Industrials):	James Lennon	+61 (0)2 9239 9618	jlennon@petracapital.com.au
Research (Industrials):	Sam Haddad	+61 (0)2 9239 9633	shaddad@petracapital.com.au
Research (Industrials):	Ken Wagner	+61 (0)2 9239 9642	kwagner@petracapital.com.au
Research (Industrials):	Daniel Ireland	+61 (0)2 9239 9647	direland@petracapital.com.au
Research (Industrials):	Mark Yarwood	+61 (0)2 9239 9646	myarwood@petracapital.com.au
Research (Healthcare):	Tanushree Jain	+61 (0)2 9239 9649	tjain@petracapital.com.au
Sales:	Frank Barila	+61 (0)2 9239 9603	fbarila@petracapital.com.au
Sales:	Vincent Pisani	+61 (0)2 9239 9617	vpisani@petracapital.com.au
Sales:	Peter Veldhuizen	+61 (0)2 9239 9609	pveldhuizen@petracapital.com.au
Sales:	Neil Watson	+61 (0)2 9239 9602	nwatson@petracapital.com.au
Sales:	Leigh Gardner	+61 (0)400 740 842	lgardner@petracapital.com.au
Sales:	Vince Barila	+61 (0)2 9239 9627	vbarila@petracapital.com.au
Sales:	Colin Redmond	+61 (0)2 9239 9613	credmond@petracapital.com.au
Sales:	Richard Macphillamy	+61 (0)2 9239 9604	rmacphillamy@petracapital.com.au
Sales:	Paul Doherty	+61 (0)407 194 549	pdoherty@petracapital.com.au
Sales:	Tyrone Lara	+61 (0)2 9239 9608	tlara@petracapital.com.au
Sales:	Vince Musumeci	+61 (0)2 9239 9606	vmusumeci@petracapital.com.au
Sales:	Andrew Richards	+61 (0)2 9239 9638	arichards@petracapital.com.au
Sales:	Rob Dobson	+61 (0)2 9239 9628	rdobson@petracapital.com.au
Sales:	Denise Wong	+61 (0)2 9239 9650	dwong@petracapital.com.au
Corporate (ECM):	Verity Barritt	+61 (0)2 9239 9622	vbarritt@petracapital.com.au
Corporate (ECM):	Louise Kissell	+61 (0)2 9239 9645	lkissell@petracapital.com.au
Administration:	Suzanne Graham	+61 (0)2 9239 9624	sgraham@petracapital.com.au
Administration:	Belinda Teichmann	+61 (0)2 9239 9636	bteichmann@petracapital.com.au
Administration:	Joanne Condopoulos	+61 (0)2 9239 9635	jcondopoulos@petracapital.com.au
Administration:	Victoria Smith	+61 (0)2 9239 9616	vsmith@petracapital.com.au
Administration:	Larissa Falvo	+61 (0)2 9239 9611	lfalvo@petracapital.com.au
Administration:	Emma Pagalday	+61 (0)2 9239 9621	epagalday@petracapital.com.au
Legal & Compliance:	Danielle Smith	+61 (0)2 9239 9612	dsmith@petracapital.com.au
Financials:	Tony Christelis	+61 (0)2 9239 9615	tchristelis@petracapital.com.au

Disclosure

This document has been prepared in Australia by Petra Capital Pty Ltd which holds an Australian Financial Services License AFSL 317 944. Petra Capital Pty Ltd is an ASX and Chi-X Market Participant. Petra Capital Pty Ltd and its associates, officers, directors, employees and agents, from time to time, may receive brokerage, commissions, fees or other benefits or advantages, hold securities in companies researched by Petra Capital Pty Ltd and may trade in these securities either as principal or agent.

Disclaimer

The information or advice contained in this report has been obtained from sources that were accurate at the time of issue, however the information has not been independently verified and as such, Petra Capital Pty Ltd cannot warrant its accuracy or reliability. Persons relying on this information do so at their own risk. To the extent permitted by law, Petra Capital Pty Ltd disclaims all liability or responsibility for any direct or indirect loss or damage (including consequential loss or damage) caused by any error or omission within this report, or by persons relying on the contents of this report.

This report is published by Petra Capital Pty Ltd by way of general information or advice only. This report does not take into account specific investment needs or other considerations that may be pertinent to individual investors. Before making any investment decisions based on this report, parties should consider, with or without an investor adviser, whether any relevant part of this report is appropriate to their financial circumstances and investment objectives. Petra Capital Pty Ltd is a licensed institutional/wholesale stockbroking firm. The report is only intended for institutional and sophisticated clients to whom Petra Capital Pty Ltd has issued the report. Petra Capital Pty Ltd is not licensed to advise retail investors – retail investors should contact their own stockbroker or financial adviser/planner for advice.

Ratings

Information regarding the scope and expertise of our research services, processes for selection for coverage, and the management of conflicts of interest can be found on Petra Capital's website at http://www.petracapital.com.au/research-disclosures. Petra Capital uses the following ratings system and definitions: Buy - Forecast to re-rate by more than 5% in 12 months; Hold - Forecast to perform up to 5% above or below the current market price in 12 months, or alternatively, where a share price exceeds Petra Capital's valuation but there is a belief that business growth opportunities or commodity price moves, may result in material valuation and share price upside within 12 months; Sell - Forecast to underperform by more than 5% in 12 months; Speculative Buy - Speculative Investment; Take Profits - Recommend taking short term profits in a stock we remain fundamentally positive on a medium term view; Accept Offer - For a company under takeover where we see the offer as a fair price with low risk of a competing offer; No Rating - No rating at this time.

US Investors

This material is intended for use in the US only by major US Institutional Investors, as that term is defined by the SEC Rule 15a-6. Transactions with US Institutional Investors and major US Institutional Investors, as those terms are defined by SEC Rule 15a-6, are chaperoned by Global Alliance Securities, LLC, ("Global Alliance"), a SEC-registered broker-dealer and FINRA member (web: www.globalalliancesecurities.com) in accordance with the agreement between Global Alliance and Petra Capital Pty Ltd. The information upon which this and material is based was obtained from sources believed to be reliable, but has not been independently verified. Therefore, its accuracy is not guaranteed. Additional and supporting information is available upon request. This is not an offer or solicitation of an offer to buy or sell any security or to make any investment. Any opinion or estimate constitutes the preparer's best judgement as of the date of preparation and is subject to change without notice. Petra Capital Pty Ltd or Global Alliance and their associates or affiliates, and their respective officers, directors and employees may buy or sell securities mentioned herein as agent or principal for their own account.

Other International

International investors are encouraged to contact their local regulatory authorities to determine whether restrictions apply in buying/selling this investment.

13 April 2023

ABN 95 110 952 782 ACN 110 952 782 AFSL 317 944